Michael Gober, MD
Dermatology · Bryn Mawr, PANPI 1154514131
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,340 of the $5,154 with a category attached, or 64.8%. Regeneron accounts for 67.7% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $3,897, more than ten times the $178 reported in 2019.
Across 87 payments — averaging $59.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$3K
- Novartis$673
- AbbVie$443
- Johnson & Johnson$126
- Pfizer$90
- Regeneron Healthcare Solutions, Inc.$58
- plus $273 from 10 others
What the payments were for
- Consulting fees$3,34065%
- Travel & lodging$371%
- Food & beverage$1,77734%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 4 | $3,491 |
| Novartis | 27 | $673 |
| AbbVie | 26 | $443 |
| Johnson & Johnson | 7 | $126 |
| Pfizer | 5 | $90 |
| Regeneron Healthcare Solutions, Inc. | 3 | $58 |
| Amgen | 3 | $54 |
| Arcutis Biotherapeutics, Inc. | 2 | $41 |
| LEO Pharma Inc. | 2 | $36 |
| Boehringer Ingelheim | 1 | $32 |
| Incyte Corporation | 1 | $25 |
| Strata Skin Sciences, Inc. | 2 | $25 |
| Almirall LLC | 1 | $23 |
| Dermavant Sciences, Inc. | 1 | $14 |
| EPI Health, LLC | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$3,454
How this compares
$5,154 in reported general payments places this provider in the 70th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 61 | $3,818 |
| Ketoconazole | 183 | $3,589 |
| Metronidazole | 52 | $3,227 |
| Clobetasol Propionate | 67 | $1,948 |
| Doxycycline Hyclate | 23 | $1,906 |
| Triamcinolone Acetonide | 169 | $1,574 |
| Fluocinonide | 25 | $1,168 |
| Mupirocin | 65 | $444 |
| Fluocinolone Acetonide | 11 | $388 |
| Ciclopirox | 11 | $247 |
| Hydrocortisone | 29 | $163 |
| Minoxidil | 15 | $130 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Bryn Mawr
- Edward RyanBryn Mawr$159K
- Scott GottliebExton$2.1M
- Douglas KressWexford$2M
- Stephen HessPhiladelphia$1.7M
- Adel HaqueYardley$1M
- Joel GelfandPhiladelphia$649K
- Neil NirenPittsburgh$574K
- Victoria WerthPhiladelphia$547K
- Mark SeralyMc Murray$545K
- Laura FerrisPittsburgh$502K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.